REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/06/2026
Back to search
Official data from USPTO
DEVELOPMENT BY DESIGN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DEVELOPMENT BY DESIGN
ST13
US500000086873967Class
1, 5, 40
Filing
86873967
Registration
5220043
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
06/07/2026
Trademark type
Word
Nice classes
1, 5, 40
Filing date
01/13/2016
Registration date
06/06/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2024
Last transaction
06/07/2026
Responsible office
United States Patent and Trademark Office
Status code
704
Official register
Supplemental Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
Cork, IE
Examiner
DESAI, BRIN ANDERSON
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Hovione Scientia Limited
Representatives
Mainak H. Mehta Procopio Cory Hargreaves & Savitch
Technical classification
Nice Classes
Class 1Class 5Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Active chemical ingredients for use in the manufacture of pharmaceuticals
Class 5
Compositions for medical and veterinarian usechemical products for pharmaceutical usechemical preparations for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disordersall of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical usechemical preparations for the preventiondiagnosistreatment or improvement of conditions and disordersinflammatoryallergicaloncologicaldegenerativegenetictraumatictumouralpressurepoisoningmutationsepsispsychiatricobeseeatingaddictivesexualsleepinfectious conditions and disordersbacterialviralfungal or parasitic conditions and disordersall of the above related to skinmusculo-skeletalcardiacneurologicalcellularvascularhematologicalrespiratorydigestivegenitalurinaryreproductivesensorialmetabolicendocrinelymphaticimmune or nervous systemsas well as pain managementfor use by humans or animals
Class 40
research and development of manufacturing processes for the pharmaceutical industry; research in the field of optimizing manufacturing processes for the pharmaceutical industry
Publications
History of USPTO decisions and trademark events.
34 publications found
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/07/2024
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
06/07/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
05/21/2024
PRA8
POST REGISTRATION ACTION MAILED - SEC. 8
11/21/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/21/2023
ES8R
TEAS SECTION 8 RECEIVED
08/08/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/06/2022
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
06/06/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/04/2017
ALIE
ASSIGNED TO LIE
04/25/2017
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
03/27/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
03/27/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/27/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
03/27/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/27/2017
ACEC
AMENDMENT FROM APPLICANT ENTERED
03/27/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/23/2017
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
09/26/2016
GNSF
SUBSEQUENT FINAL EMAILED
09/26/2016
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
09/26/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/25/2016
GNFR
FINAL REFUSAL E-MAILED
09/25/2016
CNFR
FINAL REFUSAL WRITTEN
09/25/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/26/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/25/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/25/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/25/2016
GNRT
NON-FINAL ACTION E-MAILED
02/25/2016
CNRT
NON-FINAL ACTION WRITTEN
02/25/2016
DOCK
ASSIGNED TO EXAMINER
02/18/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/19/2016
NWAP
NEW APPLICATION ENTERED
01/16/2016
Continuous trademark protection
Get notified about every new filing that threatens DEVELOPMENT BY DESIGN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.